Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Genentech Inc patents


Recent patent applications related to Genentech Inc. Genentech Inc is listed as an Agent/Assignee. Note: Genentech Inc may have other listings under different names/spellings. We're not affiliated with Genentech Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Genentech Inc-related inventors


 new patent  Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

The present disclosure provides methods for predicting responsiveness of a subject having cancer to an ox40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an ox40 agonist treatment by measuring the expression level of one or more biomarkers. ... Genentech Inc

 new patent  Methods of treating fgfr3 related conditions

Provided herein are biomarkers and therapies for the treatment of pathological conditions, such as cancer, and method of using fgfr3 antagonists. In particular, provided is fgfr3 as a biomarker for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.. ... Genentech Inc

Anti-tigit antibodies and methods of use

The invention provides anti-tigit (t-cell immunoreceptor with ig and itim domains) antibodies and methods of using the same.. . ... Genentech Inc

Pyrrolobenzodiazepine antibody drug conjugates and methods of use

The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.. . ... Genentech Inc

Pyridone and aza-pyridone compounds and methods of use

Pyridone and aza-pyridone compounds of formula i are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating immune disorders such as inflammation mediated by btk kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.. ... Genentech Inc

Multispecific antigen-binding proteins

Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the vh/vl domains and/or ch1/cl domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.. . ... Genentech Inc

Therapeutic and diagnostic methods for il-33-mediated disorders

. . The invention relates to methods of treating a patient suffering from an il-33-mediated disorder, such as asthma, comprising administering to the patient an il-33 axis binding antagonist based on the genotype of the /l1rl1gene, the genotype of a polymorphism in genomic vicinity to the il-33 gene, the expression level of periostin or the expression level of soluble st2. The invention further relates to methods of determining whether a patient is at increased risk of an il-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an il-33 axis binding antagonist, based on the genotype of the /l1rl1gene the genotype of a polymorphism in genomic vicinity to the il-33 gene, the expression level of periostin or the expression level of soluble st2.. ... Genentech Inc

Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody

The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an anti-cd20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.. . ... Genentech Inc

Antibody formulation

The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the ph in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.. . ... Genentech Inc

Inhibitors of rip1 kinase and methods of use thereof

The invention provides novel compounds having rip1 kinase inhibitory activity, pharmaceutical compositions including the compounds and methods of using the compounds.. . ... Genentech Inc

Anti-cd79b antibodies and immunoconjugates

The invention provides anti-cd79b antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

Methods of treating cancer using tigit inhibitors and anti-cancer agents

The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits tigit expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits tigit expression and/or activity, or both, as well as instructions for use thereof.. ... Genentech Inc

Predicting progression to advanced age-related macular degeneration using a polygenic score

The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (amd) who possess a greater risk of progression to advanced amd, using a polygenic score calculated based on the results of genome-wide gene association studies, using thousands of single-nucleotide polymorphisms (snps).. . ... Genentech Inc

Assembly of bispecific antibodies

Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. ... Genentech Inc

06/14/18 / #20180162951

Treatment with anti-erbb2 antibodies

The present invention concerns the treatment of cancer with anti-erbb2 antibodies.. . ... Genentech Inc

05/31/18 / #20180148510

Production of proteins in glutamine-free cell culture media

. . The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.. ... Genentech Inc

05/24/18 / #20180140700

Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor

The present invention is directed to a combination therapy involving an anti-her2 antibody-drug conjugate and a selective bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a her2-expressing cancer.. . ... Genentech Inc

05/17/18 / #20180134798

Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

The invention provides methods of dosing for the treatment of cancers, such as b cell proliferative disorders, with anti-cluster of differentiation 20 (cd20)/anti-cluster of differentiation 3 (cd3) bispecific antibodies.. . ... Genentech Inc

05/17/18 / #20180134797

Anti-transferrin receptor antibodies and methods of use

The present invention relates to anti-trans-ferrin receptor antibodies and methods of their use.. . ... Genentech Inc

05/17/18 / #20180134685

Process for the manufacturing of medicaments

The present invention provides a process for the manufacture of a compound of formula viiia and salts forms of viiia where rc is an aryl sulfonic acid. . ... Genentech Inc

05/17/18 / #20180133315

Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-cd20 antibody with a cd79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of cd20 expressing cancers with an afucosylated humanized b-ly1 antibody and a cd79b antibody-drug conjugate.. . ... Genentech Inc

05/17/18 / #20180133219

Biheteroaryl compounds and uses thereof

The present invention provides for compounds of formula i-i and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, r2, r3, x1, x2, a and cy variable in formula i-i all have the meaning as defined herein.. ... Genentech Inc

05/10/18 / #20180127393

Serine/threonine kinase inhibitors

. . . . . . Compounds of formula i or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of formula i or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.. ... Genentech Inc

05/10/18 / #20180125995

Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

The invention provides rf1 antibody antibiotic conjugates and methods of using same.. . ... Genentech Inc

05/03/18 / #20180120273

Ionic strength-mediated ph gradient ion exchange chromatography

. . The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated ph gradient ion exchange chromatography. In some aspects, the methods use a combination of ph gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. ... Genentech Inc

05/03/18 / #20180118781

Antibody purification by cation exchange chromatography

A method for purifying an antibody by cation exchange chromatography is described in which a high ph wash step is used to remove of contaminants prior to eluting the desired antibody using an elation buffer with increased conductivity.. . ... Genentech Inc

05/03/18 / #20180117152

Anti-cd3 antibodies and methods of use

The invention provides anti-cluster of differentiation 3 (cd3) antibodies and methods of using the same.. . ... Genentech Inc

05/03/18 / #20180117044

Biheteroaryl compounds and uses thereof

The present invention provides for compounds of formula i and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, r2, r3, x1, x2, a and cy variable in formula all have the meaning as defined herein.. ... Genentech Inc

05/03/18 / #20180116966

Immediate-release tablets containing a drug and processes for forming the tablets

The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.. ... Genentech Inc

04/19/18 / #20180106809

Antibodies and immunoconjugates and uses therefor

. . Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided.. ... Genentech Inc

04/19/18 / #20180105605

Antibodies and methods of use

The presently disclosed subject matter provides antibodies that bind klb and fgfr1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on fgfr1 and binds to an epitope present on klb.. ... Genentech Inc

04/12/18 / #20180100024

Humanized anti-factor d antibodies and uses thereof

The invention relates to anti-factor d antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.. ... Genentech Inc

04/12/18 / #20180100018

Fgfr1 agonists and methods of use

The invention provides nucleic acid molecules encoding anti-fibroblast growth factor receptor-1 (fgfr1) antibodies and vectors and host cells comprising the nucleic acid molecules.. . ... Genentech Inc

04/05/18 / #20180094056

Anti-her2 antibodies and methods of use

The invention provides anti-her2 antibodies, including anti-her2 antibodies of improved stability or affinity, and methods of using the same.. . ... Genentech Inc

03/29/18 / #20180086833

Integrin beta7 antagonists and methods of treating crohn's disease

. . Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including crohn's disease are provided. Also provided are methods of administering and dosing integrin beta7 antagonists, such as anti-integrin beta7 antibodies. ... Genentech Inc

03/29/18 / #20180086757

Triazolopyridine compounds and methods of use thereof

Provided are triazolopyridine compounds that are inhibitors of jak kinase, such as jak1, compositions containing these compounds and methods for treating diseases mediated by a jak kinase. In particular, provided are compounds of formula (i), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where r1a, r1b, r1c, r2, r3, r4 and r5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a jak kinase in a patient.. ... Genentech Inc

03/29/18 / #20180085470

Anti-wall teichoic antibodies and conjugates

The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.. . ... Genentech Inc

03/22/18 / #20180080080

Gene expression markers and treatment of multiple sclerosis

The present invention concerns markers of multiple sclerosis, their use, and treatment with il-17 antagonists, including il-17 antibodies, of subjects with increased levels of such markers.. . ... Genentech Inc

03/22/18 / #20180080056

Methods and compositions for preventing norleucine misincorporation into proteins

The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.. ... Genentech Inc

03/22/18 / #20180079826

Prevention and treatment of complement-associated eye conditions

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (cnv) and age-related macular degeneration (amd), by administration of factor d antagonists.. . ... Genentech Inc

03/22/18 / #20180079807

Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same

The present application relates to variants of an anti-il-17a/f antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a hmws variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-il-17a/f antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions thereof.. . ... Genentech Inc

03/22/18 / #20180079806

Chimeric fibroblast growth factors with altered receptor specificity

The present invention is directed to novel chimeric fibroblast growth factor (fgf) polypeptides, novel dna encoding chimeric fgf polypeptides, and to the recombinant production of chimeric fgf polypeptides, and to methods, compositions and assays utilizing chimeric fgf polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric fgf polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.. . ... Genentech Inc

03/15/18 / #20180071286

Heteroaryl pyridone and aza-pyrodine compounds

. . Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating immune disorders such as inflammation mediated by btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.. ... Genentech Inc

03/01/18 / #20180057598

Multivalent and multiepitopic antibodies having agonistic activity and methods of use

. . Provided herein are tetravalent antigen binding complexes having agonist activity for a cell surface receptor. In some embodiments, the complexes comprise binding specificities for multiple epitopes of the same cell surface receptor. ... Genentech Inc

03/01/18 / #20180057593

Masked anti-cd3 antibodies and methods of use

The invention provides masked anti-cluster of differentiation 3 (cd3) antibodies and methods of using the same.. . ... Genentech Inc

03/01/18 / #20180057589

Anti-notch2 nrr antibodies

The invention provides anti-notch antibodies, and in particular, antibodies that bind notch2 nrr, and methods of using the same.. . ... Genentech Inc

03/01/18 / #20180057500

Pyrazole carboxamide compounds and methods of use

Pyrazole carboxamide compounds of formula i are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk, and for treating cancer and immune disorders such as inflammation mediated by btk. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.. ... Genentech Inc

03/01/18 / #20180055927

Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a pd-1 axis binding antagonist and a taxane.. ... Genentech Inc

03/01/18 / #20180055845

Pharmaceutical compositions comprising akt protein kinase inhibitors

The present invention relates to pharmaceutical compositions comprising akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.. . ... Genentech Inc

02/15/18 / #20180044421

Anti-cll-1 antibodies and immunoconjugates

. . The invention provides anti-cll-1 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

02/15/18 / #20180044420

Anti-cll-1 antibodies and immunoconjugates

The invention provides anti-cll-1 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

02/08/18 / #20180037667

Anti-factor b antibodies and their uses

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (cnv) and age-related macular degeneration (amd), by administration of factor b antagonists.. . ... Genentech Inc

02/08/18 / #20180037662

Pertuzumab variants and evaluation thereof

The present application discloses variants of pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising cys23/cys88 unpaired cysteines in one or both variable light domains of pertuzumab, an afucosylated variant of pertuzumab, a low-molecular-weight-species (lmws) of pertuzumab, and a high-molecular-weight-species (hmws) or pertuzumab. ... Genentech Inc

02/08/18 / #20180037661

Pertuzumab variants and evaluation thereof

The present application discloses variants of pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising cys23/cys88 unpaired cysteines in one or both variable light domains of pertuzumab, an afucosylated variant of pertuzumab, a low-molecular-weight-species (lmws) of pertuzumab, and a high-molecular-weight-species (hmws) or pertuzumab. ... Genentech Inc

02/08/18 / #20180037660

Pertuzumab variants and evaluation thereof

The present application discloses variants of pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising cys23/cys88 unpaired cysteines in one or both variable light domains of pertuzumab, an afucosylated variant of pertuzumab, a low-molecular-weight-species (lmws) of pertuzumab, and a high-molecular-weight-species (hmws) or pertuzumab. ... Genentech Inc

02/08/18 / #20180037655

Therapeutic and diagnostic methods for cancer

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a pd-l1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a pd-l1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., pd-l1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.. ... Genentech Inc

02/01/18 / #20180030434

Methods of identifying bacteria comprising binding polypeptides

The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. ... Genentech Inc

02/01/18 / #20180030138

Therapeutic and diagnostic methods for cancer

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (nsclc). The invention provides methods of treating nsclc, methods of determining whether a patient suffering from nsclc is likely to respond to treatment comprising a pd-l1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from nsclc to treatment comprising a pd-l1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from nsclc, based on expression levels of a biomarker of the invention (e.g., pd-l1 expression levels in tumor cells and/or tumor-infiltrating immune cells).. ... Genentech Inc

01/25/18 / #20180022813

Antigen binding complex having agonistic activity and methods of use

Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.. ... Genentech Inc

01/25/18 / #20180021450

Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

The invention provides anti-staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.. . ... Genentech Inc

01/25/18 / #20180021431

Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

The present invention describes combination treatment comprising a pd-1 axis binding antagonist and a mek inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.. . ... Genentech Inc

01/18/18 / #20180016325

Anti-wall teichoic antibodies and conjugates

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.. . ... Genentech Inc

01/18/18 / #20180015179

Anti-cd79b antibodies and immunoconjugates

The invention provides anti-cd79b antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

01/18/18 / #20180015177

Anti-ly6e antibodies and immunoconjugates and methods of use

The invention provides anti-ly6e antibodies, immunoconjugates and methods of using the same.. . ... Genentech Inc

01/11/18 / #20180009894

Anti-cll-1 antibodies and immunoconjugates

The invention provides anti-cll-1 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

01/04/18 / #20180002433

Anti-transferrin receptor antibodies and methods of use

. . . . The present invention relates to anti-transferrin receptor antibodies and methods of their use.. . ... Genentech Inc

01/04/18 / #20180000964

Blood brain barrier receptor antibodies and methods of use

The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.. . ... Genentech Inc

01/04/18 / #20180000833

Serine/threonine kinase inhibitors

Compounds having the formula i wherein r1, x1, x2, x3 and x4 as defined herein are inhibitors of erk kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.. ... Genentech Inc

12/28/17 / #20170370906

Bioanalytical analysis of site-specific antibody drug conjugates

. . Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.. . ... Genentech Inc

12/28/17 / #20170369885

Treatment of th17 mediated inflammatory diseases

The present invention provides methods and means to reduce inflammation associated with irf-4, ap-1 and th17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions.. ... Genentech Inc

12/28/17 / #20170369869

Expression and secretion system

The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.. ... Genentech Inc

12/28/17 / #20170369564

Anti-vegf antibodies

Humanized and variant anti-vegf antibodies and various uses therefor are disclosed. The anti-vegf antibodies have strong binding affinities for vegf; inhibit vegf-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.. ... Genentech Inc

12/28/17 / #20170368039

Novel compounds and compositions for the inhibition of nampt

The present invention relates to compounds and compositions for the inhibition of nampt, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:. ... Genentech Inc

12/21/17 / #20170362318

Compositions and methods for the treatment of tumor hematopoietic origin

. . The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.. . ... Genentech Inc

12/21/17 / #20170360928

Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing egfr, as determined by a gene amplification assay, with an egfr antagonist. Such method comprises administering a cancer-treating dose of the egfr antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbb1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. ... Genentech Inc

12/07/17 / #20170349664

Methods for treating progressive multiple sclerosis

The present invention concerns methods for treating progressive multiple sclerosis (ms) in a patient, and an article of manufacture with instructions for such use.. . ... Genentech Inc

12/07/17 / #20170349639

Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders

The present invention provides for chimeric wnt antagonists comprising a frz domain component derived from a frizzled protein, a secreted frizzled related protein or ror protein and an fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular wnt signaling and wnt-mediated disorders, including cancer.. . ... Genentech Inc

12/07/17 / #20170349573

Hedgehog antagonists having zinc binding moieties

The present invention provides compounds which antagonize hedgehog signaling and inhibit hdac activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.. ... Genentech Inc

12/07/17 / #20170348422

Silvestrol antibody-drug conjugates and methods of use

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.. ... Genentech Inc

12/07/17 / #20170348310

Serine/threonine kinase inhibitors

Compounds of formula i or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of formula i or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.. ... Genentech Inc

11/30/17 / #20170342488

Methods of using fgf19 modulators

Provided herein are methods of using fgf19 modulators and/or bile acid metabolism biomarkers.. . ... Genentech Inc

11/30/17 / #20170342163

Anti-htra1 antibodies and methods of use

The invention provides anti-htra1 antibodies and methods of using the same.. . ... Genentech Inc

11/30/17 / #20170339928

Animal model for nephropathy and agents for treating the same

A non-human transgenic animal expressing apol1 is provided as well as a method for generating the same. Also provided is a method for identifying an agent capable of reducing the progression of an apol1 mediated nephropathy. ... Genentech Inc

11/23/17 / #20170334985

Anti-il-13/il-17 bispecific antibodies and uses thereof

The invention provides anti-il-13/il-17 bispecific antibodies, in particular, anti-il13/il17 aa, af and ff antibodies and methods of using the same, including without limitation, methods of using the anti-il-13/il-17 bispecific antibodies for treating moderate to severe asthma and/or eosinophilic asthma.. . ... Genentech Inc

11/16/17 / #20170327574

Methods of treating liver conditions using notch2 antagonists

Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising notch2 antagonists, e.g., anti-notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.. ... Genentech Inc

11/16/17 / #20170326248

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-cd22 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

11/09/17 / #20170321187

Biologically active c-terminal arginine-containing peptides

. . The present invention concerns the separation, identification and characterization of active peptide fragments from peptones.. . ... Genentech Inc

11/09/17 / #20170320940

Anti-alpha-synuclein antibodies and methods of use

The present invention relates to anti-alpha-synuclein (anti-α-synuclein) antibodies and methods of using the same.. . ... Genentech Inc

11/09/17 / #20170320937

Anti-influenza b virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza b virus hemagglutinin antibodies, compositions comprising anti-influenza b virus hemagglutinin antibodies, and methods of using the same.. . ... Genentech Inc

11/09/17 / #20170320926

Il-22 polypeptides and il-22 fc fusion proteins and methods of use

The invention relates to il-22 polypeptides, il-22 fc fusion proteins and il-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to il-22 receptor associated reagents and methods of use thereof.. ... Genentech Inc

11/09/17 / #20170319688

Anti-rspo3 antibodies and methods of use

Provided herein are anti-rspo3 antibodies and methods of using the same.. . ... Genentech Inc

10/26/17 / #20170306419

Diagnostic markers

The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the erbb2 gene. One aspect of the invention provides a method of predicting response to an egfr inhibitor therapy based on the methylation status of the erbb2 gene.. ... Genentech Inc

10/26/17 / #20170306418

Therapeutic, diagnostic, and prognostic methods for cancer

The invention provides methods and compositions to detect expression of one or more biornarkers, including fgfr3, tp53, and/or egfr, for treating, diagnosing, and providing a prognosis for cancer, e.g., bladder cancer. The invention also provides kits and articles of manufacture for use in the methods.. ... Genentech Inc

10/26/17 / #20170306040

Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-cd20 antibody with a cd22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of cd20 expressing cancers with an afucosylated humanized b-ly1 antibody and a cd22 antibody-drug conjugate.. . ... Genentech Inc

10/26/17 / #20170304438

Methods of using anti-cd79b immunoconjugates

Provided herein are methods of treating b-cell proliferative disorders in particular follicular lymphoma and/or diffuse large b-cell lymphoma using immunoconjugates comprising anti-cd79b antibodies in combination with additional therapeutic agents.. . ... Genentech Inc

10/12/17 / #20170291940

Il-17a/f heterologous polypeptides and therapeutic uses thereof

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. ... Genentech Inc

10/12/17 / #20170290920

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-cd22 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

10/12/17 / #20170290913

Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

The invention provides compositions and methods for treating cancers. The method comprises administering a pd-1 axis binding antagonist and an ox40 binding agonist.. ... Genentech Inc

10/12/17 / #20170290883

Vascular disruption agents and uses thereof

Uses of apo2l/trail polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.. ... Genentech Inc

10/05/17 / #20170283505

Production of proteins in glutamine-free cell culture media

The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.. ... Genentech Inc

10/05/17 / #20170283424

Pyrazolopyrimidine jak inhibitor compounds and methods

A compound of formula i, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are defined herein, are useful as inhibitors of one or more janus kinases. A pharmaceutical composition that includes a compound of formula i and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a janus kinase activity in a patient are disclosed.. ... Genentech Inc

10/05/17 / #20170281792

Anti-mesothelin antibodies and immunoconjugates

The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

09/28/17 / #20170276683

Elisa for vegf

The vascular endothelial growth factor (vegf) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich elisa methods and kits for vegf as an antigen are provided to detect types of vegf levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.. ... Genentech Inc

09/28/17 / #20170275359

Anti-ephrinb2 antibodies and methods using same

The invention provides anti-ephrinb2 antibodies, and compositions comprising and methods of using these antibodies.. . ... Genentech Inc

09/28/17 / #20170275273

Estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.. ... Genentech Inc

09/28/17 / #20170274092

Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines

The invention provides immunoconjugates comprising anti-her2 antibodies and methods of using the same.. . ... Genentech Inc

09/28/17 / #20170274073

Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists

The present disclosure provides methods comprising administering to the individual an effective amount of a pd-1 axis binding antagonist and an il-17 binding antagonist. Further provided are kits comprising a pd-1 axis binding antagonist, an il-17 binding antagonist, or both, as well as instructions for use thereof.. ... Genentech Inc

09/14/17 / #20170260594

Methods and compositions for prognosis and treatment of cancers

The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.. ... Genentech Inc

09/14/17 / #20170260292

Low affinity blood brain barrier receptor antibodies and uses thereof

The present invention relates to antibodies that bind blood brain barrier receptors (bbb-r) and methods of using the same.. . ... Genentech Inc

09/14/17 / #20170260253

Cysteine engineered antibodies and conjugates

Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the pheselector assay. ... Genentech Inc

09/14/17 / #20170260252

Production of heteromultimeric proteins using mammalian cells

Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.. ... Genentech Inc

09/07/17 / #20170253933

Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

. . The invention provides methods of using expression levels of one or more stroma signature genes as selection criteria for determining a patient with cancer that is chemotherapy-resistant who may benefit from a particular anti-cancer therapy, such as stroma-targeted therapy, anti-angiogenic therapy, and/or immunotherapy. The present invention also provides methods of using expression levels of one or more stroma signature genes as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a stroma-targeted agent.. ... Genentech Inc

09/07/17 / #20170253661

Galactoengineered immunoglobulin 1 antibodies

The present invention relates to galactoengineered recombinant antibodies of igg1 isotype, methods for the production of said antibodies and uses thereof.. . ... Genentech Inc

08/31/17 / #20170247381

Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase

. . The invention relates generally to pharmaceutical tablet compositions comprising fumaric acid and the compound (s)-2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one free base that is an inhibitor of bruton's tyrosine kinase. The invention further relates to amorphous solid dispersions comprising at least one polymer and the bruton's kinase inhibitor free base compound. ... Genentech Inc

08/31/17 / #20170247338

Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (r)-4-(5-methyl-7-oxo-6,7-dihydro-5h-cyclopenta[d] pyrimidin-4-yl)piperazine and n-protected derivatives thereof, which may be used as an intermediate in the synthesis of ipatasertib (i.e., (s)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.. ... Genentech Inc

08/24/17 / #20170240645

Anti-pmel17 antibodies and immunoconjugates

The invention provides anti-pmel17 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

08/24/17 / #20170240620

Anti-polyubiquitin antibodies and methods of use

The invention provides anti-polyubiquitin antibodies and methods of using the same.. . ... Genentech Inc

08/24/17 / #20170239366

Anti-b7-h4 antibodies and immunoconjugates

The invention provides anti-b7-h4 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

08/24/17 / #20170239355

Use of tryptophan derivatives for protein formulations

The invention provides methods and formulations comprising a protein comprising solvent accessible amino acid residues susceptible to oxidation wherein n-acetyl tryptophan (nat) is used to prevent oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. ... Genentech Inc

08/24/17 / #20170239219

Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer

Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer.. . ... Genentech Inc

08/17/17 / #20170234883

Antibodies and immunoconjugates and uses therefor

. . Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided.. ... Genentech Inc

08/17/17 / #20170233809

Methods for diagnosing and treating inflammatory bowel disease

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and crohn's disease are provided. ... Genentech Inc

08/17/17 / #20170233486

Polynucleotides encoding anti-notch1 nrr antibody polypeptides

The invention provides anti-notch1 nrr antibodies, and compositions comprising and methods of using these antibodies.. . ... Genentech Inc

08/17/17 / #20170233482

Combination therapy

The invention provides for the treatment of diseases or disorders characterized by cells expressing the cd40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing cd40 with a combination of an agent causes the depletion of cells expressing cd40 and a second agent which causes the depletion of cells expressing the cd20 membrane antigen. ... Genentech Inc

08/17/17 / #20170233471

Anti-lgr5 antibodies and uses thereof

The invention provides anti-lgr5 antibodies and methods of using the same.. . ... Genentech Inc

08/17/17 / #20170232113

Quaternary amine compounds and antibody-drug conjugates thereof

This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.. . ... Genentech Inc

08/10/17 / #20170226224

Protein purification

A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or ph of buffers in order to resolve a polypeptide of interest from one or more contaminants.. . ... Genentech Inc

08/10/17 / #20170226198

Predicting response to a vegf antagonist

The invention describes the use of high cd31 and/or tumor vegfa as selection criteria for determining patient benefit or responsiveness to a vegf antagonist, such as bevacizumab. The present invention also describes the use of high cd31 and/or tumor vegfa as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a vegf antagonist, such as bevacizumab.. ... Genentech Inc

08/10/17 / #20170226132

Triazolopyridine compounds, compositions and methods of use thereof

Compounds of formula 0, formula i and formula ii and methods of use as janus kinase inhibitors are described herein.. . ... Genentech Inc

08/10/17 / #20170224820

Compositions and methods useful for stabilizing protein-containing formulations

The invention relates to use of non-surfactant compounds including, for example, polyoxyethylene (poe) sorbitans and polyethylene glycols (pegs), for stabilizing protein-containing formulations and for the prevention of aggregation of proteins in such formulations.. . ... Genentech Inc

07/27/17 / #20170210815

Compositions and methods for diagnosis and treatment of hepatic cancers

. . . . The present invention relates to methods of treating liver cancer using a notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.. ... Genentech Inc

07/27/17 / #20170210807

Humanized anti-beta7 antagonists and uses therefor

The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.. . ... Genentech Inc

07/27/17 / #20170209593

Methods of conjugating an agent to a thiol moiety in a protein that contains at least one sulfide bond

The invention provides improved methods of conjugating an agent to a thiol moiety in a protein that contains at least one disulfide bond and at least one trisulfide bond. Exemplary embodiments include the production of antibody drug conjugates substantially free of impurities created in the presence of reactive sulfide moieties in the production processes.. ... Genentech Inc

07/27/17 / #20170209444

Methods of treating cancer and preventing cancer drug resistance

Provided herein are methods of using antagonists of g9a, for example, for treating cancer and/or preventing drug resistance in an individual. For example, a method of treating cancer in an individual comprising administering to the individual an antagonist of g9a alone or in combination with a cancer therapy agent is provided. ... Genentech Inc

07/20/17 / #20170204194

Anti-cd3 antibodies and methods of use

The invention provides anti-cluster of differentiation 3 (cd3) antibodies and methods of using the same.. . ... Genentech Inc

07/20/17 / #20170204188

Anti-fgfr3 antibodies and methods using same

The invention provides fgfr3 antibodies, and compositions comprising and methods of using these antibodies.. . ... Genentech Inc

07/20/17 / #20170204187

Methods of treating and preventing cancer drug resistance

Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of fgfr signaling and a b-raf antagonist.. . ... Genentech Inc

07/20/17 / #20170204135

Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration

The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.. . ... Genentech Inc

07/20/17 / #20170202973

Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1

Methods of treating patients having metastatic or unresectable locally advanced her2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-mcc-dm1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab.. . ... Genentech Inc

07/13/17 / #20170198030

Methods of treating alzheimer's disease

Methods of treating alzheimer's disease (ad) in patients suffering from mild to moderate ad, including apoe4 positive patients and patients suffering from mild ad are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-abeta antibody. ... Genentech Inc

07/13/17 / #20170196837

Formulations with reduced oxidation

The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. ... Genentech Inc

07/06/17 / #20170191102

Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase

The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering rna (sirna) specific for a lactate dehydrogenase (ldh) and b) an sirna specific for a pyruvate dehydrogenase kinase (pdhk). ... Genentech Inc

07/06/17 / #20170190786

Anti-erbb2 antibodies

Anti-erbb2 antibodies are described which bind to an epitope in domain 1 of erbb2 and induce cell death via apoptosis. Various uses for these antibodies are also described.. ... Genentech Inc

07/06/17 / #20170189536

Formulations with reduced degradation of polysorbate

The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. ... Genentech Inc

06/29/17 / #20170183740

Cancer treatment with c-met antagonists and correlation of the latter with hgf expression

The present invention concerns cancer biomarkers. In particular, the invention concerns hgf as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.. ... Genentech Inc

06/22/17 / #20170174785

Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof

. . A composition comprising a main species her2 antibody that binds to domain ii of her2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.. ... Genentech Inc

06/22/17 / #20170174782

Anti-her2 antibodies and immunoconjugates

The invention provides anti-her2 antibodies and immunoconjugates and methods of using the same.. . ... Genentech Inc

06/22/17 / #20170174733

Chagasin-based scaffold compositions, methods, and uses

Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. ... Genentech Inc

06/15/17 / #20170166656

Anti-her2 antibody variants

. . The present invention concerns novel antibody variants, particularly anti-her2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains. . ... Genentech Inc

06/15/17 / #20170166636

Anti-lrp5 antibodies and methods of use

The invention provides anti-lrp5 antibodies and methods of making and using the same.. . ... Genentech Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Genentech Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Genentech Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###